Neola Medical (STO:NEOLA) Third Quarter 2024 Results
Key Financial Results
- Revenue: kr1.74m (down 2.9% from 3Q 2023).
- Net loss: kr2.29m (loss narrowed by 3.3% from 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Neola Medical Earnings Insights
Looking ahead, revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden.
Performance of the Swedish Medical Equipment industry.
The company's shares are down 8.4% from a week ago.
Risk Analysis
Before you take the next step you should know about the 6 warning signs for Neola Medical (2 are a bit unpleasant!) that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if Neola Medical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:NEOLA
Neola Medical
Develops medical equipment for continuous monitoring of the lungs of premature babies.
Medium-low with excellent balance sheet.
